Skip to main content
. 2022 Dec 17;22:526. doi: 10.1186/s12876-022-02602-5

Table 2.

Anti-tumor effect of both groups

Total (n = 54) NRT group (n = 28) NCRT group (n = 26)
Complete response, n (%) 6 (11.1%) 2 (7.1%) 4 (15.4%)
Partial response, n (%) 44 (81.5%) 23 (82.1%) 21 (80.8%)
Stable disease, n (%) 2 (3.7%) 2 (7.1%) 0 (0)
Progressive disease, n (%) 2 (3.7%) 1 (3.6%) 1 (3.8%)
Objective response rate 92.6% 89.2% 96.2%
Median OS, months 16.0 9.0 24.0
Median PFS, months 10.0 7.0 17.0

NRT, nimotuzumab + radiotherapy; NCRT, nimotuzumab + chemo-radiotherapy; OS, overall survival; PFS, progression-free survival